Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

811
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
811
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

724
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
724
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

2.0K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
2.0K
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

939
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
939
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

812
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
812
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

331
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
331

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immunoadsorption in dilated cardiomyopathy: the IASO-DCM trial.

European heart journal·2026
Same author

Association of NK cells with a shift in tryptophan catabolism in patients with heart failure after a single exercise exertion.

Frontiers in immunology·2026
Same author

Sex-dependent associations of childhood maltreatment with obesity-related traits: results from the German National Cohort (NAKO).

International journal of obesity (2005)·2026
Same author

Mechanical circulatory support for cardiogenic shock in takotsubo syndrome.

Clinical research in cardiology : official journal of the German Cardiac Society·2026
Same author

Deep learning to predict left ventricular hypertrophy from the electrocardiogram.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology·2026
Same author

Effects of Exercise Duration and Intensity on Maximal Exercise Capacity Over 6 Months in Coronary Heart Disease and Type 2 Diabetes-A Secondary Analysis of the LeIKDTrial.

Scandinavian journal of medicine & science in sports·2026

Related Experiment Video

Updated: Apr 19, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

12.4K

Immunoadsorption therapy in dilated cardiomyopathy.

Stephan B Felix1, Daniel Beug, Marcus Dörr

  • 1Department of Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.

Expert Review of Cardiovascular Therapy
|December 16, 2014
PubMed
Summary

Dilated cardiomyopathy treatment may involve removing cardiac autoantibodies via immunoadsorption. This experimental therapy shows promise for improving heart function and reducing inflammation in patients with this heart muscle disease.

Keywords:
cardiac antibodiesdilated cardiomyopathyhumoral immune systemimmunoadsorptionimmunomodulationmyocardial inflammation

More Related Videos

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.6K
Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
12:46

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

Published on: August 17, 2022

3.2K

Related Experiment Videos

Last Updated: Apr 19, 2026

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes
13:42

Measurement of Antibody Effects on Cellular Function of Isolated Cardiomyocytes

Published on: March 8, 2013

12.4K
A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
05:14

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo

Published on: May 16, 2020

5.6K
Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells
12:46

Flow Cytometry-Based Quantification and Analysis of Myocardial B-Cells

Published on: August 17, 2022

3.2K

Area of Science:

  • Cardiology
  • Immunology
  • Heart Failure Research

Background:

  • Dilated cardiomyopathy involves ventricular enlargement and dysfunction, leading to heart failure.
  • Genetic factors, viral infections, and inflammation contribute to dilated cardiomyopathy.
  • Cardiac autoantibodies from humoral immune system activation are implicated in disease progression.

Purpose of the Study:

  • To investigate the role of cardiac autoantibodies in dilated cardiomyopathy.
  • To evaluate the efficacy of immunoadsorption in treating dilated cardiomyopathy.

Main Methods:

  • Review of experimental and clinical studies on dilated cardiomyopathy.
  • Analysis of outcomes from small open-controlled studies using immunoadsorption.

Main Results:

  • Humoral immune system activation and cardiac autoantibodies are functionally significant in dilated cardiomyopathy.
  • Immunoadsorption demonstrated improvement in cardiac function.
  • Immunoadsorption led to a decrease in myocardial inflammation.

Conclusions:

  • Immunoadsorption is a potential experimental treatment for dilated cardiomyopathy.
  • Further placebo-controlled multicenter studies are required to confirm the efficacy of immunoadsorption therapy.